Gonadotropin-releasing Hormone Analog
Sponsors
Rutgers, The State University of New Jersey, M.D. Anderson Cancer Center, University of Washington, Mayo Clinic
Conditions
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Sensitive Prostate AdenocarcinomaLocally Advanced Unresectable HER2-Negative Breast CarcinomaLocally Advanced Unresectable Hormone Receptor-Positive Breast CarcinomaMetastatic Castration-Sensitive Prostate AdenocarcinomaMetastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
Phase 2
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Active, not recruitingNCT02949284
Start: 2017-06-20End: 2027-06-30Target: 90Updated: 2026-01-07
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
CompletedNCT03279250
Start: 2017-10-13End: 2021-05-11Updated: 2022-08-10
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
RecruitingNCT06179303
Start: 2024-07-22End: 2028-06-01Target: 60Updated: 2026-02-27
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
RecruitingNCT06369610
Start: 2024-04-22End: 2027-04-22Target: 110Updated: 2025-11-14
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
Not yet recruitingNCT07466498
Start: 2026-08-01End: 2029-06-01Target: 60Updated: 2026-03-12